Please note: The information displayed on this page might be outdated.
PROSION: A pharmaceutical drug discovery company offering proline derived modules (ProMs) as the world’s first proline-rich-motive (PRM) structure mimicking building blocks. Based on its disruptive ProM-platform, PROSION develops a new class of drugs and is able to address yet undruggable considered targets that are related to various indications. Among those targets is Ena/VASP, a marker of pancreatic & breast carcinogenesis and potential game-changer in oncology. For its first of many potential use-cases, PROSION has already shown a remarkable in vivo effect of its ProM-based anti-metastatic inhibitor – both in pancreatic and breast cancer xenograft rodent models.
Life Sciences, Pharmaceuticals, Specialty Pharmaceutical
pi3k, Platform Technology, Small Molecule
Company Participants at Fall Private Company Showcase 2021
- Slim Chiha, Co-founder & CEO